Clinical trial
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With…
NCT04980222 · Hoffmann-La Roche, Industry · Active, not recruiting
Key facts
| NCT number | NCT04980222 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma |
| Official title | A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide |
| Enrollment | 46 |
| Start date | Mar 22, 2022 |
| Primary completion | Sep 30, 2026 |
| Completion | Sep 30, 2026 |
| First posted | Jul 28, 2021 |
| Last update posted | Nov 18, 2025 |
| Countries | Denmark, France, Netherlands, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: